NNNN
NASDAQ · Biotechnology
Anbio Biotechnology Ltd
$3.89
+0.30 (+8.36%)
Financial Highlights (FY 2026)
Revenue
26.29M
Net Income
19.47M
Gross Margin
87.2%
Profit Margin
74.1%
Rev Growth
-28.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.2% | 87.2% | 30.8% | 30.8% |
| Operating Margin | 66.7% | 60.0% | -15.2% | -16.7% |
| Profit Margin | 74.1% | 70.4% | -19.2% | -20.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 26.29M | 36.72M | 1.84B | 1.79B |
| Gross Profit | 22.94M | 32.03M | 567.81M | 552.88M |
| Operating Income | 17.54M | 22.04M | -280,071,476 | -300,415,133 |
| Net Income | 19.47M | 24.47M | -354,337,532 | -367,227,211 |
| Gross Margin | 87.2% | 87.2% | 30.8% | 30.8% |
| Operating Margin | 66.7% | 60.0% | -15.2% | -16.7% |
| Profit Margin | 74.1% | 70.4% | -19.2% | -20.5% |
| Rev Growth | -28.4% | -28.4% | +17.6% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 886.33M | 752.45M |
| Total Equity | — | — | 1.73B | 1.94B |
| D/E Ratio | — | — | 0.51 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 17.54M | 23.27M | -454,323,212 | -381,836,603 |
| Free Cash Flow | — | — | -249,462,362 | -276,575,086 |